Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $54.40.

TWST has been the subject of a number of research analyst reports. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th.

Twist Bioscience Trading Up 1.3 %

Shares of TWST stock opened at $41.33 on Thursday. Twist Bioscience has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The stock’s fifty day moving average price is $47.74 and its two-hundred day moving average price is $45.67. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a market cap of $2.47 billion, a PE ratio of -12.23 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. Equities analysts predict that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Chess sold 3,504 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40. Following the completion of the sale, the director now directly owns 21,641 shares in the company, valued at approximately $1,122,085.85. This represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,180 shares of company stock worth $1,821,971. Insiders own 3.01% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience in the 3rd quarter worth about $34,000. Van ECK Associates Corp grew its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Signaturefd LLC grew its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. Banque Transatlantique SA acquired a new position in Twist Bioscience in the fourth quarter valued at approximately $43,000. Finally, GF Fund Management CO. LTD. acquired a new position in Twist Bioscience in the fourth quarter valued at approximately $58,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.